Uromedica
- Company typePrivate
- Founded1997
- HeadquartersPlymouth, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Uromedica firmographics
Firmographics- Name
- Uromedica
- Legal name
- Uromedica, Inc.
- Website
- https://uromedica-inc.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Uromedica industry classification
Industry- Product category
- Urology Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Urinary Catheters & Drainage (Intermittent/Foley Catheters, Bags, Securement) (HLAHALAI)
- akta.pro secondary industry
- Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies) (HSABAKAH)
Keywords
Where Uromedica is headquartered
LocationHeadquarters
- HQ city
- Plymouth
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Uromedica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- ProACT Device Sales: Uromedica generates revenue through the sale of its ProACT and ACT implantable medical devices to hospitals and urologists. The devices are billed using CPT codes 53451-53454, with the ProACT device billed using C-code C1889 (unlisted device). The company sells directly to healthcare facilities for implantation in patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical device sales to healthcare facilities |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
Uromedica product offering
Product offeringCore offering
Uromedica develops and sells the ProACT (men) and ACT (women) adjustable continence therapy systems — implantable silicone balloon devices connected via tubing to subcutaneous ports that treat stress urinary incontinence. The devices are implanted in a minimally invasive day-case procedure and allow physicians to post-operatively adjust balloon volume in an office setting without additional surgery. ProACT is FDA-approved and commercially available in the US; ACT is CE-marked and sold in Europe, Canada, and Australia while remaining investigational in the US.
Product overview
Uromedica offers two core products under its Adjustable Continence Therapy platform: ProACT™ for men and ACT® for women. Both are minimally invasive, implantable balloon therapy devices designed to treat stress urinary incontinence through post-operative adjustability without requiring additional surgery. ProACT received FDA approval in 2015 and has been commercially available in the US since late 2017, while ACT remains investigational in the US but holds CE Mark approval and is available in Europe, Canada, and Australia. Together, the products have been implanted in over 16,000 patients worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- ProACT: Adjustable Continence Therapy device for men (ProACT) designed to treat male stress urinary incontinence resulting from radical prostatectomy or TURP. FDA approved and commercially available in the USA since 2015.
- ACT
Products and services
- ProACT (Adjustable Continence Therapy for Men) ProACT is an FDA-approved implantable medical device consisting of two small, adjustable silicone balloons connected via tubing to subcutaneous ports, placed bilaterally in the periurethral position to treat male stress urinary incontinence following radical prostatectomy or TURP. The device is post-operatively adjustable in an office setting without requiring additional surgery, is indicated for all severity levels of SUI, and can be completely removed in an office under topical anesthesia.
- ACT (Adjustable Continence Therapy for Women) ACT is an adjustable continence therapy device consisting of two small silicone balloons implanted on either side of the bladder neck via a minimally invasive outpatient procedure to treat female stress urinary incontinence resulting from intrinsic sphincter deficiency. The device is CE Mark approved and sold in Europe, Canada, and Australia but remains investigational and not available for sale in the United States.
Quantifiable outcome
- Patient IQOL scores improved an average of 30.8 points (66.2%) from baseline
- +4 more outcomes
Companies that use Uromedica
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Uromedica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Uromedica partnerships and signals
Strategic signalScale indicators7 records
Recent moves5 records
Expansion highlights4 records
Uromedica competitors and assessment
Company assessmentBroad incumbents
- Cook Medical: Cook Medical has a meaningful urology and continence-care device portfolio (including stone management and pelvic floor products) overlapping with Uromedica's target customer base of urologists.
- Hollister Incorporated: Hollister offers continence, ostomy, and intermittent catheter products serving the same end-patient population (post-prostatectomy and SUI sufferers) that Uromedica's ProACT addresses.
- Convatec: Convatec operates a large continence care franchise (catheters, absorbent products) addressing the broader incontinence patient pool that includes candidates for Uromedica's ACT/ProACT devices.
- Becton Dickinson (BD): BD's Urology and Critical Care segment sells urinary drainage catheters, continence products, and surgical urology devices, overlapping with the procedural urology space Uromedica serves.
- Coloplast: Coloplast is the acquirer of Uromedica (closing Feb 2026) and a global leader in continence care with its own sling and catheter portfolios; directly comparable as a larger incumbent now integrating ProACT/ACT into its urology franchise.
Direct peers
- Boston Scientific: Boston Scientific (via American Medical Systems / AMS) manufactures the AMS800 artificial urinary sphincter and AdVance male sling, the dominant alternatives to Uromedica's ProACT for male stress urinary incontinence.
- Caldera Medical: Caldera Medical develops and commercializes surgical mesh slings (e.g., Desara, Ascend) for female stress urinary incontinence — the same clinical indication Uromedica's ACT targets.
- Wellspect Healthcare: Wellspect (a Mölnlycke Health Care subsidiary) makes LoFric hydrophilic intermittent catheters — clinically adjacent to Uromedica's catheter-adjacent continence therapy for the post-prostatectomy SUI population.
Emerging players
- Promedon: Promedon (Argentina-based) manufactures suburethral slings (e.g., Unitape TOT, Ophira mini-sling) for female SUI, competing in the same surgical female SUI market where Uromedica's ACT is positioned ex-US.
- Laborie Medical Technologies: Laborie (owned by Patricia Industries/Investor AB) offers urodynamics, pelvic floor, and sling products for SUI diagnostics and treatment, targeting the same urology specialty channel as Uromedica.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Uromedica social profiles
Digital presenceUromedica compliance and trust
Trust signalCompliance3 records
Uromedica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Uromedica leadership team
Management profileNumber of profiles
Profiles6 records
Uromedica funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Uromedica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Uromedica
What does Uromedica do?
Uromedica develops and sells the ProACT (men) and ACT (women) adjustable continence therapy systems — implantable silicone balloon devices connected via tubing to subcutaneous ports that treat stress urinary incontinence. The devices are implanted in a minimally invasive day-case procedure and allow physicians to post-operatively adjust balloon volume in an office setting without additional surgery. ProACT is FDA-approved and commercially available in the US; ACT is CE-marked and sold in Europe, Canada, and Australia while remaining investigational in the US.
Is Uromedica a public or private company?
Uromedica is a private company. It is classified as founder individual operated bootstrapped and is currently acquired.
When was Uromedica founded?
Uromedica was founded in 1997. It employs 11 to 50 people.
Where is Uromedica based?
Uromedica is headquartered in Plymouth, United States, in the North America region.
How does Uromedica make money?
One revenue line is on record: proACT Device Sales.
Who are Uromedica's main competitors?
Broad incumbents on record are Cook Medical, Hollister Incorporated, Convatec, Becton Dickinson (BD) and Coloplast. Direct peers are Boston Scientific, Caldera Medical and Wellspect Healthcare. Emerging players are Promedon and Laborie Medical Technologies.
Does Uromedica have an API?
No public API is recorded for Uromedica.
What industry is Uromedica in?
Uromedica's product category is Urology Medical Devices. Its primary akta.pro industry code is HLAHALAI, Urinary Catheters & Drainage (Intermittent/Foley Catheters, Bags, Securement), with a secondary code of HSABAKAH, Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies). Its NAICS code is 339112 and its SIC code is 3841.